Skip to Content

Plantar Fasciitis

Plantar fasciitis (PF) is a painful localized inflammatory condition which is frequently associated with debilitating pain in the heel and bottom of the foot, significantly impairing mobility. DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020.

Not an actual patient

1M

Estimated number of patient visits per year attributed to PF.1

1 in 10

Estimated number of U.S. adults who will suffer from PF in their lifetime.1,2

$284M

Estimated PF U.S. treatment market2

Plantar Fasciitis might heal after several months with conservative treatments like ice, stretches, and common pain-relievers. Many cases require steroid injections, physical therapy, shock-wave therapy or surgery. Currently, there are no FDA-approved drug treatments for this debilitating yet common condition. An approved pharmacological treatment would potentially provide a significant step forward for this patient population. Plantar fasciitis is typically treated by podiatrists and orthopedic surgeons.

Enrollment for the Phase 2 placebo-controlled clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis was completed in December 2019 and topline results are expected in fall of 2020.

References

1. Plantar Fasciitis. Medscape. Retrieved from: https://emedicine.medscape.com/article/86143-overview. Accessed 9/29/2020

2. Rosenbaum AJ, et al. Plantar Heel Pain. Med Clin N Am 98. 2014: 339–352

Back to top